Funding for this research was provided by:
National Human Genome Research Institute (UM1 HG0089001, U01 HG007417, U01 HG009610, R01 HG010297, U01 HG009080)
National Heart, Lung, and Blood Institute (R01 HL104608, X01 HL1345)
National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK110113)
Received: 8 July 2019
Accepted: 13 November 2019
First Online: 31 December 2019
Ethics approval and consent to participate
: The Icahn School of Medicine at Mount Sinai’s Institutional Review Board approved this study (protocol number 18-1771), including a waiver of informed consent and a HIPAA waiver of authorization. The study population consisted of 30,223 participants aged 18 years or older from Mount Sinai’s Bio<i>Me</i> Biobank (protocol number 07-0529). This research conformed to the Declaration of Helsinki.
: N.S.A-H. was previously employed by Regeneron Pharmaceuticals and has received a speaker honorarium from Genentech. E.E.K has received speaker honoraria from Illumina and Regeneron Pharmaceuticals. The remaining authors declare no competing interests.